Thechronic obstructive pulmonary disease(COPD) market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations(LABA/ICSFDCs) toward LABA/long-acting muscarinic antagonist (LAMA) FDCs and even LABA/LAMA/ICSFDCs, but current and emerging generics will have a significant impact on this trend. Some branded generic and generic LABA/ICSFDCs have already launched in the United States and Europe, and more will reach the market in the near future; because cost remains a significant driver, we expect competition from these generics to affect the uptake of both LABA/LAMA and LABA/LAMA/ICSFDCs. Physicians are eager to have alternative treatments for this chronic disease, and the development of novel drug classes continues.
- How will markets react to the launch / uptake of generic LABA/ICSFDCs and tiotropium? Will there be significant country-to-country differences in uptake of these generics?
- Will LABA/LAMAFDCs continue to gain market share, or will generic therapies or branded LABA/LAMA/ICSFDCs threaten these agents?
- What proportion of patients currently receive a combination of two or more therapies in separate inhalers? How many receive triple therapy, and will these patients be shifted to FDCs?
- Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.